methodology used to assess the insulin concentration. In addition, ADA has reviewed and confirmed that the insulin manufacturers strictly adhere to and document quality control procedures throughout the supply chain to meet the USP standards recognized by the FDA to ensure safety, potency and efficacy of insulin. 4 On the background of the article by Carter and Heinemann and given the importance of insulin quality on patient outcomes, we evaluated insulin concentrations in vials from three different sources: (1) we analyzed insulin content and stability based on production batches covering 7 years of production, (2) we measured insulin content from the last three years of insulin samples returned to Novo Nordisk from patients in the United States because of concerns expressed by the patients, and (3) we reviewed data from 10 years of independent European Medicines Association (EMA) sampling and testing of products.
Methods

Analysis of Insulin Concentration and Stability of Production Batches Covering Seven Years of Production
Analysis of insulin concentration and stability of production batches covering seven years of production of NPH insulin: Insulatard® (named Novolin® N in the United States; Novo Nordisk A/S, Bagsvaerd, Denmark) and regular human insulin Actrapid® (named Novolin® R in the United States; Novo Nordisk A/S).
For Insulatard, the analyses are based on stability data from 88 batches covering 7 years of production (n = 761 tested samples), and for Actrapid the analyses are based on stability data from 85 batches covering 7 years of production (n = 855 tested samples).
Actrapid was analyzed for impact on insulin concentration under the following two conditions:
As per label: Stored for 30 months at 5°C and handled as per procedure during the cold-chain transport, that is, inspected, labeled and packed, and transported at 5 ± 3°C and during pharmacy storage. Samples were left at 30 C for 6 weeks to mimic in-use impact. The degradation due to excursions from 5 ± 3°C is included in the specification limits. Stressed conditions: Stored for 30 months at 5°C and handled as per procedure during the cold-chain transport, that is, inspected, labeled and packed, and transported at 5 ± 3°C and during pharmacy storage. Samples were left for additional 4 weeks in 30°C to mimic non recommended handling conditions and then left at 30°C for 6 weeks to mimic in-use impact. The degradation due to excursions from 5 ± 3°C is included in the specification limits.
Insulatard was analyzed for impact on insulin concentration under the following two conditions:
As per label: Stored for 30 months at 5°C and handled as per procedure during the cold-chain transport and the pharmacy storage and left at 30°C for additional 6 weeks to mimic in-use impact. Stressed conditions: Stored for 30 months at 5°C and handled as per procedure during the cold-chain transport and the pharmacy storage as well as left for 4 more weeks in 30°C to mimic non recommended handling conditions and then left at 30°C for additional 6 weeks to mimic in-use impact.
Insulin concentrations were measured using reverse phase-high pressure liquid chromatography (RP-HPLC) according to regulatory standards (European Pharmacopeia, United States Pharmacopeia, Japanese Pharmacopeia: 3.7.17 method description for identity, assay and related products of Human Insulin). 3, 5, 6 This method requires minimal sample preparation.
A total of 4 µL of 6 M hydrochloric acid per mL is added to the insulin preparation to be examined followed by 10 minutes rotation mixing prior to RP-HPLC analysis. Acidification ensures dissolution of all insulin crystals and dissociates insulin hexamers into monomers for both reference and test sample. The chromatographic separation is selective and there is no interference between excipient components and insulin peak in the chromatogram. The insulin peak in the test sample is easily quantified against insulin peak in the chromatogram of the reference sample. This method has been correlated to bioactive insulin through extensive testing for decades and has been accepted as the standard analysis method for accurate and precise measurement of bioactive insulin in insulin drug formulations by the different regulatory authorities and the US Pharmacopeia. 3, 5, 6 
Analysis of Last 3 Years of Returned Insulin Samples From US Patients
To evaluate the insulin concentration in the vials used by patients, we assessed insulin samples returned by patients in the United States. A detailed analysis was performed in Denmark on 233 samples of Actrapid and Insulatard. Insulin concentrations were measured using RP-HPLC as utilized for the production batches.
The European Medicines Agency
In accordance with European Parliament regulation, EMA has the responsibility to coordinate and supervise the quality of the medicinal products by requesting testing of compliance with their authorized specifications by the official medicinal control laboratories or by a laboratory a member state has designated for that purpose. 7 In accordance with this the EMA organizes an annual Sampling and Testing Programme for Centrally Authorised Products. Some of these products included insulin containing products from Novo Nordisk. The products were selected for inclusion using a risk based methodology. The EMA purchased Novo Nordisk insulins from pharmacies and wholesalers, and tested the samples to confirm compliance with insulin content specification. We have collected this infor- 
Results
The evaluation of the impact from shelf life storage, cold-chain transport and pharmacy handling, and in-use conditions on insulin concentrations of Actrapid and Insulatard is based on data from stability studies of insulin production batches covering 7 years of production. These were followed for stability at 3 different temperatures. For Insulatard the analyses are based on stability data from 88 batches covering 7 years of production (n = 761 tested samples), and for Actrapid the analyses are based on stability data from 85 batches covering 7 years of production (n = 855 tested samples). The data demonstrated that even at scenarios that stressed the normal recommendations for temperature storage conditions, the resulting impact on insulin concentrations, that is, 4.0 IU/ml and 1.4 IU/ml for Actrapid and Insulatard, remained within the acceptable limits outlined in the FDA standards ( Table 1) . None of the samples were outside FDA specifications. The analysis was based on stability data from 85 or more insulin production batches covering 7 years of production. The method validation for Actrapid showed a repeatability of 0.1361% relative standard deviation (RSD) and an intermediate precision of 0.2529% RSD ( Table 2 ). The method validation for Insulatard showed a repeatability of 0.2332% RSD and an intermediate precision of 0.3762% RSD ( Table 2 ).
An analysis of insulin returned to Novo Nordisk by patients in the United States due to concerns about its effectiveness for the period January 5, 2015, to January 5, 2018, for Actrapid (Novo Nordisk A/S) and Insulatard (Novo Nordisk A/S) revealed that in the 233 vials returned from the US patients in the last 3 years showed an average assay concentration of 98.5 IU/ml with a standard deviation of 6.7 and 2.4; respectively (Table 3 ). The vials were returned to Novo Nordisk by individual patients in the United States over concerns that a particular vial or penfill® of insulin was The estimation is based on stability studies data from insulin production batches covering 7 years of production of Actrapid and Insulatard. Only five vials, four of Insulatard and one of Actrapid, fell below 95 U/ml. The four vials on Insulatard had at least 50% of insulin removed and had evidence of inhomogeneous extraction (inadequate mixing). The contents of the vial of Actrapid had evidence of contamination with another liquid. All data were included in the analyses above, as also indicated by the standard deviations.
ineffective in controlling blood glucose levels or the patient noted a crack in the insulin vial. There has been no recent increase in the number of vials returned to Novo Nordisk over the last several years and no safety signal relating to lack of efficacy of fast or long-acting human insulin in the United States has been identified when assessing the adverse event database over last 3 years. The data from EMA testing of insulin content also confirmed compliance with required specification for 7 different insulins from 2007 to 2017 (Table 4 ).
Discussion
Our data on insulin production quality confirm that insulin delivered to pharmacies and when in use by patients meets the required regulatory standards and provides no evidence of concern about insulin content. Our results include analyses of insulin samples that were returned to Novo Nordisk "for cause" and were outside the recommended cold chain during their return by shipping to Novo Nordisk. These are exactly the type of samples that might be predicted to contain degraded insulin, since transportation of these samples occurs via post, but insulin content met specifications. Our results are further supported with 100% compliance in EMA quality controls of Novo Nordisk insulins over the last 10 years.
Carter and Heinemann implicated the cold supply chain for the low insulin concentrations observed in their study. The cold supply chain is the temperature controlled supply chain for insulins. However, a previous study from Chandler et al modeled the impact of transit temperature excursions on the potency of insulin (regular, NPH, and 70/30) and demonstrated that the potency would be maintained in accordance with US Pharmacopeia 9 under the conditions that they tested.
The low insulin concentration observed by Carter and Heinemann, may be explained by the analytical method utilized in the study. Insulin content was measured using quadrapole time-of-flight mass spectrometer along with LC-MS.
2 LC-MS is a very sensitive and specific method and can quantify insulin in human plasma from 0.2 to 25 ng/mL (0.45 pmol/L to 56.17 pmol/L). 10 However, the sample preparation in this method requires extensive dilution that poses a significant risk for loss of the analyte. In addition, sample preparation may result in insufficient dissociation of insulin hexamers causing a false decrease of insulin content in the assay. It is also important to note that the QTOF/LC-MS method used in the study was not validated to quantify insulin as outlined by regulatory authorities. This has also been corroborated in the response letter to the Carter and Heinemann publication from Eli Lilly 11 and the response letter from the ADA, Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Charitable trust. 12 In our study, the RP-HPLC method that is the recognized standard for assessing insulin content was utilized. This assay requires minimum sample preparation and results in 100% dissociation of insulin hexamers to monomers. This ensures insulin content is quantified with high precision and robustness, as demonstrated in our results. Furthermore, the HPLC assay has been widely validated for determining biopotency. [13] [14] [15] RP-HPLC methodology has been used to quantify insulin potency in insulin drug products since the late 1980s and has been acknowledged by the regulatory authorities to provide a reliable quantification of insulin content and biopotency. 15 Due to high precision and robustness of the RP-HPLC based methods, these have been adopted in all major pharmacopeia monographs for human insulin since the 1990s. 
Conclusion
The data reported here provides a comprehensive analysis of insulin concentrations in commercially available samples. We also measured insulin concentrations in a much larger sample size compared to the study by Carter and Heinemann. However, the methodology used to analyze insulin was different between the two studies. We also did 
